166 related articles for article (PubMed ID: 11918453)
1. Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.
Osby E; Liliemark E; Björkholm M; Liliemark J
Med Oncol; 2001; 18(4):269-75. PubMed ID: 11918453
[TBL] [Abstract][Full Text] [Related]
2. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
Edick MJ; Gajjar A; Mahmoud HH; van de Poll ME; Harrison PL; Panetta JC; Rivera GK; Ribeiro RC; Sandlund JT; Boyett JM; Pui CH; Relling MV
J Clin Oncol; 2003 Apr; 21(7):1340-6. PubMed ID: 12663724
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
5. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
6. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
7. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy.
Schwartsmann G; Sprinz E; Kromfield M; Kalakun L; Sander E; Prolla G; Di Leone L; Gerhardt L; Mans DR
J Clin Oncol; 1997 May; 15(5):2118-24. PubMed ID: 9164226
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Am J Clin Oncol; 1997 Jun; 20(3):311-4. PubMed ID: 9167761
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
Toubai T; Tanaka J; Mori A; Hashino S; Kobayashi S; Ota S; Miura Y; Kato N; Kahata K; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Toyoshima N; Asaka M; Imamura M
Clin Transplant; 2004 Oct; 18(5):552-7. PubMed ID: 15344959
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.
Evans SR; Krown SE; Testa MA; Cooley TP; Von Roenn JH
J Clin Oncol; 2002 Aug; 20(15):3236-41. PubMed ID: 12149296
[TBL] [Abstract][Full Text] [Related]
15. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR
Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839
[TBL] [Abstract][Full Text] [Related]
19. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
20. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]